Relationship between metabolic reprogramming and mitochondrial activity in cancer cells. Understanding the anticancer effect of metformin and its clinical implications

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 5789-5796

  Cazzaniga, Massimiliano ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Metabolic reprogramming; Metformin; Mitochondria; Review

Indexed keywords

ADENOSINE TRIPHOSPHATE; BERBERINE; CURCUMIN; EPIGALLOCATECHIN GALLATE; GLUCOSE; INSULIN; METFORMIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESVERATROL; TUMOR SUPPRESSOR PROTEIN; ANTIDIABETIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER PATIENT; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DRUG EFFICACY; ENERGY METABOLISM; ENERGY YIELD; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NEOPLASM; NUCLEAR REPROGRAMMING; ONCOGENE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; METABOLISM; NEOPLASMS; PROGNOSIS;

ENERGY METABOLISM; GLYCOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MITOCHONDRIA; NEOPLASMS; PROGNOSIS;

EID: 84946022666     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
2. Lunt SY and Vander Heiden MG: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441-464, 2011.
3. Hensley CT, Wasti AT and DeBerardinis RJ: Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 123: 3678-3684, 2013.
4. Wallace DC: Mitochondria and cancer. Nat Rev Cancer 12: 685-698, 2012.
5. Romero-Garcia S, Lopez-Gonzalez JS, Báez-Viveros JL, Aguilar-Cazares D and Prado-Garcia H: Tumor cell metabolism: an integral view. Cancer Biol Ther 12: 939-948, 2011.
6. Zheng J: Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett 4: 1151-1157, 2012.
7. Annibaldi A and Widmann C: Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 13: 466-470, 2010.
8. DeBerardinis RJ, Cheng T: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324, 2010.
9. Barwick T, Bencherif B, Mountz JM and Avril N: Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 30: 908-917, 2009.
10. Yeung SJ, Pan J and Lee MH: Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci 65: 3981-3999, 2008.
11. Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, Enge M, Kel A and Selivanova G: Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting the Warburg effect to fight cancer. J Biol Chem 286: 41600-41615, 2011.
12. Shaw RJ: Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598-608, 2006.
13. Jones W and Bianchi K: Aerobic glycolysis: beyond proliferation. Front Immunol 6: 227, 2015.
14. Daye D and Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23: 362-369, 2012.
15. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
16. Kim MH and Kim H: Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. J Cancer Prev 18: 221-226, 2013.
17. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
18. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells FEBS Journal 274: 1393-1418, 2007.
19. Barbosa IA, Machado NG, Skildum AJ, Scott PM and Oliveira PJ: Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochimica and Biophysica Acta 1826: 238-254, 2012.
20. Sullivan LB and Chandel NS: Mitochondrial reactive oxygen species and cancer. Cancer Metab 2: 17, 2014.
21. Weinberg F and Chandel NS: Mitochondrial metabolism and cancer. Ann NY Acad Sci 1177: 66-73, 2009.
22. Sabharwal SS and Schumacker PT: Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles' heel? Nat Rev Cancer 14: 709-721, 2014.
23. Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337, 2011.
24. Amoêdo ND, Valencia JP, Rodrigues MF, Galina A and Rumjanek FD: How does the metabolism of tumour cells differ from that of normal cells? Biosci Rep 33: 865-873, 2013.
25. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, Michaud M, Zischka H, Castedo M and Kroemer G: Mitochondrial gateways to cancer. Mol Aspects Med 31: 1-20, 2010.
26. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim JW, Yustein JT, Lee LA and Dang CV: Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25: 6225-6234, 2005.
27. Mishra P and Chan DC: Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol 15: 634-646, 2014.
28. Ward PS and Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308, 2012.
29. Wang C and Youle RJ: The role of mitochondria in apoptosis. Annu Rev Genet 43: 95-118, 2009.
30. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45: 487-498, 2012.
31. Desagher S and Martinou JC: Mitochondria as the central control point of apoptosis. Trends Cell Biol 10: 369-377, 2000.
32. Elkholi R, Renault TT, Serasinghe MN and Chipuk JE: Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab 2: 16, 2014.
33. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM: The role of p53 in apoptosis. Discov Med 9: 145-152, 2010.
34. Hata AN, Engelman JA and Faber AC: The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov 5: 475-487, 2015.
35. Kim R, Emi M and Tanabe K: The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5: 1429-1442, 2006.
36. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E and Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
37. Mizushima N and Komatsu M: Autophagy: renovation of cells and tissues. Cell 147: 728-741, 2011.
38. Dorn GW 2nd and Kitsis RN: The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res 116: 167-182, 2015.
39. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM and Kroemer G: Autophagy in malignant transformation and cancer progression. EMBO J 34: 856-880, 2015.
40. Iurlaro R, León-Annicchiarico CL and Muñoz-Pinedo C: Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol 542: 59-80, 2014.
41. Zwaans BM and Lombard DB: Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Model Mech 7: 1023-1032, 2014.
42. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293, 2005.
43. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL and Thompson CB: The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173, 2005.
44. Justus CR, Sanderlin EJ and Yang LV: Molecular connections between cancer cell metabolism and the tumor microenvironment. Int J Mol Sci 16: 11055-11086, 2015.
45. Miller DM, Thomas SD, Islam A, Muench D and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res 18: 5546-5553, 2012.
46. Dang CV, Le A and Gao P: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483, 2009.
47. Podar K and Anderson KC: A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 9: 1722-1728, 2010.
48. Morrish F and Hockenbery D: MYC and mitochondrial biogenesis. Cold Spring Harb Perspect Med 4(5): pii: a014225, 2014.
49. Wahlström T and Arsenian Henriksson M: Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta 1849: 563-569, 2015.
50. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007.
51. Muller PA and Vousden KH: Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25: 304-317, 2014.
52. Maddocks OD and Vousden KH: Metabolic regulation by p53. J Mol Med 89: 237-245, 2011.
53. Ma W, Sung HJ, Park JY, Matoba S and Hwang PM: A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 39: 243-246, 2007.
54. Gottlieb E and Vousden KH: p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2(4): a001040, 2010.
55. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, McCord JM and Harman D: Oxygen radicals and human disease. Ann Intern Med 107: 526-545, 1987.
56. Trachootham D, Lu W, Ogasawara MA, Nilsa RD and Huang P: Redox regulation of cell survival. Antioxid Redox Signal 10: 1343-1374, 2008.
57. Bellot GL, Liu D and Pervaiz S. ROS, autophagy, mitochondria and cancer: Ras, the hidden master? Mitochondrion 13: 155-162, 2013.
58. Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 417: 1-13, 2009.
59. Nemoto S and Finkel T: Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-2452, 2002.
60. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
61. Hielscher A, Gerecht S. Hypoxia and free radicals: role in tumor progression and the use of engineering-based platforms to address these relationships. Free Radic Biol Med 79: 281-291, 2015.
62. Sassi N, Mattarei A, Azzolini M, Szabo' I, Paradisi C, Zoratti M and Biasutto L: Cytotoxicity of mitochondria-targeted resveratrol derivatives: interactions with respiratory chain complexes and ATP synthase. Biochim Biophys Acta 1837: 1781-1789, 2014.
63. Diogo CV, Machado NG, Barbosa IA, Serafim TL, Burgeiro A and Oliveira PJ: Berberine as a promising safe anti-cancer agent-Is there a role for mitochondria? Curr Drug Targets 12: 850-859, 2011.
64. Kim HS, Quon MJ and Kim JA: New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2: 187-195, 2014.
65. Wang S, Chen R, Zhong Z, Shi Z, Chen M and Wang Y: Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells. Am J Chin Med 42: 1279-1300, 2014.
66. Trujillo J, Granados-Castro LF, Zazueta C, Andérica-Romero AC, Chirino YI and Pedraza-Chaverrí J: Mitochondria as a target in the therapeutic properties of curcumin. Arch Pharm 347: 873-884, 2014.
67. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. 330: 1304-1305, 2005.
68. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258, 2006.
69. Rena G, Pearson ER and Sakamoto K: Molecular mechanism of action of metformin: Old or new insights? Diabetologia 56: 1898-1906, 2013.
70. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS and Chandel NS: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3: e02242, 2014.
71. Salani B, Del Rio A, Marini C, Sambuceti G, Cordera R and Maggi D: Metformin, cancer and glucose metabolism Endocr Relat Cancer 21: R461-471, 2014.
72. Pollak MN: Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2: 778-790, 2012.
73. Howlett HC and Bailey CJ: A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 20: 489-503, 1999.
74. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging 4: 320-329, 2012.
75. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M and Schwab M: Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One 6: e22163, 2011.
76. Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE and Imyanitov EN: Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle 12: 3681-3688, 2013.